SCHEMBL1964099

SCHEMBL1964099

COC(=O)c1c(O)c2cc(Cl)cn2n(Cc2ccc(OC)cc2)c1=O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSP90B1 P14625 1/20 0.41
ERCC5 P28715 3/20 0.41
FEN1 P39748 4/20 0.40
KDM4E B2RXH2 2/20 0.40
HTT P42858 1/20 0.40
ALDH1A1 P00352 3/20 0.39
TP53 P04637 1/20 0.39
MAPT P10636 1/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
LMNA P02545 1/20 0.39
HPGD P15428 1/20 0.39
CCR2 P41597 1/20 0.39
MAPK8 P45983 1/20 0.39
HDAC11 Q96DB2 2/20 0.39
HDAC8 Q9BY41 2/20 0.39
HDAC6 Q9UBN7 2/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
ATM Q13315 1/20 0.39
HDAC3 O15379 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1966780 0.92 MAPT (0.41) HSP90B1KDM4EALDH1A1MAPTLMNA
SCHEMBL1969294 0.89 HSP90AA1 (0.41) HSP90B1KDM4EHTTALDH1A1TP53
SCHEMBL1966356 0.87 AR (0.40) ALDH1A1MAPTMAPK8MEN1KMT2A
SCHEMBL1970228 0.87 HIF1A (0.52) KDM4EHTTSMN1; SMN2
SCHEMBL1965536 0.86 KDM4E (0.45) KDM4EALDH1A1SMN1; SMN2LMNAMAPK8
SCHEMBL1966695 0.84 FEN1 (0.40) ERCC5FEN1KDM4EHTTSMN1; SMN2
SCHEMBL1966699 0.84 FEN1 (0.40) ERCC5FEN1KDM4EHTTSMN1; SMN2
SCHEMBL1969464 0.83 ITGB1 (0.41) ERCC5FEN1KDM4EHTTSMN1; SMN2
SCHEMBL1969468 0.83 ITGB1 (0.41) ERCC5FEN1KDM4EHTTSMN1; SMN2
SCHEMBL1966964 0.83 KDM4E (0.47) HSP90B1FEN1KDM4EHTTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2334682-B1 PYRROLO [ 1, 2 -B] PYRIDAZINE DERIVATIVES AND THEIR USE AS HIF MODULATORS FIBROGEN INC (US) 2017-10-04 EP disclosed
US-8217043-B2 Compounds and methods for their use FIBROGEN, INC. (US) 2012-07-10 US disclosed
EP-2334682-A1 PYRROLO [ 1, 2 -B] PYRIDAZINE DERIVATIVES AND THEIR USE AS HIF MODULATORS Fibrogen, Inc. (US) 2011-06-22 EP disclosed
WO-2010022240-A1 PYRROLO [ 1, 2 -B] PYRIDAZINE DERIVATIVES AND THEIR USE AS HIF MODULATORS FIBROGEN, INC. (US) 2010-02-25 WO disclosed
US-20100047367-A1 COMPOUNDS AND METHODS FOR THEIR USE FIBROGEN, INC. 2010-02-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100047367-A1 COMPOUNDS AND METHODS FOR THEIR USE HIF1AN, HIF1A, EGLN3 HSP90B1 108/4885ERCC5 1610/4885FEN1 1106/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.